Commentaries

Transplant After Transplant: Outcomes Unraveled

Szer, Jeff MBBS¹

¹
Clinical Haematology at Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, VIC, Australia.

Received 16 December 2024. Revision received 26 December 2024.

Accepted 30 December 2024.

J.S. received honoraria from and has served as an advisory board member and on the speakers bureau for Alexion Pharmaceuticals (AstraZeneca Rare Diseases), Sobi Pharmaceuticals, and Novartis. J.S. received honoraria from Eli Lilly.

J.S. was responsible for the content and writing of this article.

Correspondence: Jeff Szer, MBBS, Clinical Haematology at Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, 300 Grattan St, Parkville, Melbourne, VIC 3050, Australia. ([email protected]).

Transplantation 109(10):p 1570-1571, October 2025. | DOI: 10.1097/TP.0000000000005398

Transplant After Transplant: Outcomes Unraveled

1

Corresponding Article

Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) and Organ Procurement and Transplantation Network (OPTN) Study

¹